Spero Therapeutics Inc is a pharmaceutical company that focuses on developing novel treatments for serious infections. The company's corporate philosophy is centered around innovation, collaboration, and patient-centricity. By embracing cutting-edge science and fostering collaborations with leading researchers, Spero Therapeutics Inc aims to address the significant unmet medical needs in the field of infectious diseases. Their values include a commitment to scientific excellence, dedication to patient well-being, and a passion for improving global public health. Through their research and development efforts, Spero Therapeutics Inc strives to make a positive impact on the lives of patients and revolutionize the treatment landscape for infectious diseases.

Spero Therapeutics Inc is primarily present in the United States.

Spero Therapeutics Inc, a leading biopharmaceutical company, has achieved remarkable milestones in its journey. The company successfully completed a Phase 1 clinical trial for its novel product candidate, SPR206, designed to combat multi-drug resistant infections. Additionally, Spero Therapeutics Inc received a contract from the Biomedical Advanced Research and Development Authority (BARDA) for the development of SPR720, an oral antibiotic. These accomplishments reinforce Spero Therapeutics Inc's commitment to addressing unmet medical needs and delivering innovative solutions for patients. Through their unwavering dedication and cutting-edge research, Spero Therapeutics Inc continues to make substantial strides in the field of antibacterial therapy.

Spero Therapeutics Inc is a pharmaceutical company focused on developing novel treatments for drug-resistant bacterial infections. Founded in 2013, the company is headquartered in Cambridge, Massachusetts. Spero Therapeutics is dedicated to addressing the urgent global need for effective antibiotics, as the rise of antibiotic resistance has become a major public health concern. The company utilizes its proprietary platform to identify and develop potent drugs that target a wide range of bacteria. By harnessing innovative science and advanced research, Spero Therapeutics aims to provide hope for patients suffering from serious and life-threatening infections.

Some of the main competitors of Spero Therapeutics Inc in the market include biopharmaceutical companies like Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These competitors are also engaged in researching and developing innovative therapies for infectious diseases, with a focus on combating drug-resistant bacteria.

Spero Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Spero Therapeutics Inc is centered around developing and commercializing novel treatments for multi-drug-resistant bacterial infections. They aim to address the urgent need for new antibiotics to combat the growing threat of antibiotic resistance. Spero Therapeutics Inc utilizes its platform, including its proprietary Potentiator Platform, to discover and design potential drugs that can enhance the therapeutic efficacy of existing antibiotics and overcome resistance mechanisms. By focusing on serious bacterial infections that have limited treatment options, Spero Therapeutics Inc strives to provide better healthcare solutions for patients in need.

KGV за Spero Therapeutics в момента не може да бъде изчислено.

KUV за Spero Therapeutics в момента не може да бъде изчислено.

AlleAktien качественият резултат не може да бъде изчислен в момента за Spero Therapeutics.

Приходите не могат да бъдат изчислени в момента за Spero Therapeutics.

Печалбата за Spero Therapeutics в момента не може да бъде изчислена.

Spero Therapeutics Inc. is a biopharmaceutical company focused on the development of new antibiotics to combat antibiotic resistance. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Spero Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Spero Therapeutics е US84833T1034.

WKN на Spero Therapeutics е A2H63F.

Тикерът на Spero Therapeutics е SPRO.

През последните 12 месеца Spero Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Spero Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Spero Therapeutics в момента е .

Spero Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците април, април, юли, октомври.

Spero Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Spero Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Spero Therapeutics на 7.10.2015 г. в размер на 0,015 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 16.09.2015 г..

Последното дивидентно плащане беше извършено на 7.10.2015 г..

През година 2023 Spero Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Spero Therapeutics се изплащат в USD.